A novel small-molecule PPI inhibitor targeting integrin α v β 3 -osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice

Doori Park, Chan Won Park, Young Jin Choi, Jingjing Lin, Dong Hyun Seo, Hansung Kim, Soo Young Lee, In Cheol Kang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Small molecule-inhibition targeting protein-protein interaction (PPI) is now recognized as an emerging and challenging area in drug design. We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting-edge PPI assay system applicable for unique PPI-targeting therapeutics integrated with computer-aided drug design (CADD). Here, we describe a novel small molecular PPI inhibitor, IPS-02001, which the blocks integrin α v β 3 -osteopontin interface a novel PPI inhibitor identified by the interactive methodology of both ProteoChip- and CADD-based PPI assay. IPS-02001 (6,7-Dichloro-2,3,5,8-tetrahydroxy-1,4-naphthoquinone) was screened from different compound libraries (InterBioScreen, Commercial libraries) using an in silico structure-based molecular docking simulation method and a protein chip-based protein-protein interaction assay system. Additionally, integrin α v β 3 , an adhesion receptor expressed in osteoclasts (OCs), was implicated in the regulation of OC function via regulation of the cytoskeletal organization of OCs. IPS-02001 blocked OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs. Moreover, treatment with IPS-02001 impaired downstream signaling of integrin α v β 3 linked to Pyk2, c-Src, PLCγ2, and Vav3 and disrupted the actin cytoskeleton in mature OCs. Furthermore, IPS-02001 blocked RANKL-induced bone destruction by reducing the number of OCs and protected against ovariectomy-induced bone loss in mice. Thus, IPS-02001 may represent a promising new class of anti-resorptive drugs for treatment of bone diseases associated with increased OC function.

Original languageEnglish
Pages (from-to)131-142
Number of pages12
JournalBiomaterials
Volume98
DOIs
Publication statusPublished - 2016 Aug 1

Fingerprint

Osteopontin
Bone Resorption
Integrins
Bone
Osteoclasts
Proteins
Bone and Bones
Molecules
Drug Design
Computer-Aided Design
Protein Array Analysis
Protein Transport
Assays
Libraries
In Vitro Techniques
Molecular Docking Simulation
Pharmaceutical Preparations
Bone Diseases
Ovariectomy
Drug Discovery

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Park, Doori ; Park, Chan Won ; Choi, Young Jin ; Lin, Jingjing ; Seo, Dong Hyun ; Kim, Hansung ; Lee, Soo Young ; Kang, In Cheol. / A novel small-molecule PPI inhibitor targeting integrin α v β 3 -osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice In: Biomaterials. 2016 ; Vol. 98. pp. 131-142.
@article{814989d5d05b4fe3b3729ae6d16ad50f,
title = "A novel small-molecule PPI inhibitor targeting integrin α v β 3 -osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice",
abstract = "Small molecule-inhibition targeting protein-protein interaction (PPI) is now recognized as an emerging and challenging area in drug design. We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting-edge PPI assay system applicable for unique PPI-targeting therapeutics integrated with computer-aided drug design (CADD). Here, we describe a novel small molecular PPI inhibitor, IPS-02001, which the blocks integrin α v β 3 -osteopontin interface a novel PPI inhibitor identified by the interactive methodology of both ProteoChip- and CADD-based PPI assay. IPS-02001 (6,7-Dichloro-2,3,5,8-tetrahydroxy-1,4-naphthoquinone) was screened from different compound libraries (InterBioScreen, Commercial libraries) using an in silico structure-based molecular docking simulation method and a protein chip-based protein-protein interaction assay system. Additionally, integrin α v β 3 , an adhesion receptor expressed in osteoclasts (OCs), was implicated in the regulation of OC function via regulation of the cytoskeletal organization of OCs. IPS-02001 blocked OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs. Moreover, treatment with IPS-02001 impaired downstream signaling of integrin α v β 3 linked to Pyk2, c-Src, PLCγ2, and Vav3 and disrupted the actin cytoskeleton in mature OCs. Furthermore, IPS-02001 blocked RANKL-induced bone destruction by reducing the number of OCs and protected against ovariectomy-induced bone loss in mice. Thus, IPS-02001 may represent a promising new class of anti-resorptive drugs for treatment of bone diseases associated with increased OC function.",
author = "Doori Park and Park, {Chan Won} and Choi, {Young Jin} and Jingjing Lin and Seo, {Dong Hyun} and Hansung Kim and Lee, {Soo Young} and Kang, {In Cheol}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.biomaterials.2016.05.007",
language = "English",
volume = "98",
pages = "131--142",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",

}

A novel small-molecule PPI inhibitor targeting integrin α v β 3 -osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice . / Park, Doori; Park, Chan Won; Choi, Young Jin; Lin, Jingjing; Seo, Dong Hyun; Kim, Hansung; Lee, Soo Young; Kang, In Cheol.

In: Biomaterials, Vol. 98, 01.08.2016, p. 131-142.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel small-molecule PPI inhibitor targeting integrin α v β 3 -osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice

AU - Park, Doori

AU - Park, Chan Won

AU - Choi, Young Jin

AU - Lin, Jingjing

AU - Seo, Dong Hyun

AU - Kim, Hansung

AU - Lee, Soo Young

AU - Kang, In Cheol

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Small molecule-inhibition targeting protein-protein interaction (PPI) is now recognized as an emerging and challenging area in drug design. We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting-edge PPI assay system applicable for unique PPI-targeting therapeutics integrated with computer-aided drug design (CADD). Here, we describe a novel small molecular PPI inhibitor, IPS-02001, which the blocks integrin α v β 3 -osteopontin interface a novel PPI inhibitor identified by the interactive methodology of both ProteoChip- and CADD-based PPI assay. IPS-02001 (6,7-Dichloro-2,3,5,8-tetrahydroxy-1,4-naphthoquinone) was screened from different compound libraries (InterBioScreen, Commercial libraries) using an in silico structure-based molecular docking simulation method and a protein chip-based protein-protein interaction assay system. Additionally, integrin α v β 3 , an adhesion receptor expressed in osteoclasts (OCs), was implicated in the regulation of OC function via regulation of the cytoskeletal organization of OCs. IPS-02001 blocked OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs. Moreover, treatment with IPS-02001 impaired downstream signaling of integrin α v β 3 linked to Pyk2, c-Src, PLCγ2, and Vav3 and disrupted the actin cytoskeleton in mature OCs. Furthermore, IPS-02001 blocked RANKL-induced bone destruction by reducing the number of OCs and protected against ovariectomy-induced bone loss in mice. Thus, IPS-02001 may represent a promising new class of anti-resorptive drugs for treatment of bone diseases associated with increased OC function.

AB - Small molecule-inhibition targeting protein-protein interaction (PPI) is now recognized as an emerging and challenging area in drug design. We developed a novel interactive drug discovery methodology known as Protein Chip technology (ProteoChip) as a cutting-edge PPI assay system applicable for unique PPI-targeting therapeutics integrated with computer-aided drug design (CADD). Here, we describe a novel small molecular PPI inhibitor, IPS-02001, which the blocks integrin α v β 3 -osteopontin interface a novel PPI inhibitor identified by the interactive methodology of both ProteoChip- and CADD-based PPI assay. IPS-02001 (6,7-Dichloro-2,3,5,8-tetrahydroxy-1,4-naphthoquinone) was screened from different compound libraries (InterBioScreen, Commercial libraries) using an in silico structure-based molecular docking simulation method and a protein chip-based protein-protein interaction assay system. Additionally, integrin α v β 3 , an adhesion receptor expressed in osteoclasts (OCs), was implicated in the regulation of OC function via regulation of the cytoskeletal organization of OCs. IPS-02001 blocked OC maturation from murine bone marrow-derived macrophages, as well as the resorptive function of OCs. Moreover, treatment with IPS-02001 impaired downstream signaling of integrin α v β 3 linked to Pyk2, c-Src, PLCγ2, and Vav3 and disrupted the actin cytoskeleton in mature OCs. Furthermore, IPS-02001 blocked RANKL-induced bone destruction by reducing the number of OCs and protected against ovariectomy-induced bone loss in mice. Thus, IPS-02001 may represent a promising new class of anti-resorptive drugs for treatment of bone diseases associated with increased OC function.

UR - http://www.scopus.com/inward/record.url?scp=84966697301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966697301&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.05.007

DO - 10.1016/j.biomaterials.2016.05.007

M3 - Article

C2 - 27187277

AN - SCOPUS:84966697301

VL - 98

SP - 131

EP - 142

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -